CAZZANIGA, MARINA ELENA

CAZZANIGA, MARINA ELENA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 145 (tempo di esecuzione: 0.066 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review 01 - Articolo su rivista 2026 Clementi, Thoma DarioCazzaniga, Marina Elena +
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 01 - Articolo su rivista 2026 D'Amato D.Bernasconi D.Facciotti F.Gerussi A.Rossi E.Cazzaniga M. E.Ippolito D.Galimberti S.Invernizzi P.Carbone M. +
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study 01 - Articolo su rivista 2026 Cazzaniga, M. E.Galimberti, S. +
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 01 - Articolo su rivista 2025 Cazzaniga, MECordani, NGalimberti, S +
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC) 01 - Articolo su rivista 2025 Clementi, Thoma DarioCazzaniga, Marina Elena +
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 01 - Articolo su rivista 2025 Malighetti, FedericaVilla, MatteoPelucchi, SaraAroldi, AndreaCortinovis, Diego LuigiCazzaniga, Marina ElenaMologni, LucaRamazzotti, DanieleCordani, Nicoletta +
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study 01 - Articolo su rivista 2025 Cazzaniga M. E. +
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP) 01 - Articolo su rivista 2025 Cazzaniga M. +
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer 01 - Articolo su rivista 2025 Cazzaniga M. +
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 01 - Articolo su rivista 2024 Cazzaniga M. E.Zambelli A. +
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160) 99 - Altro 2024 Cazzaniga M. +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 01 - Articolo su rivista 2024 Foti G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M.Bellani G.Bruno R.Biondi A.Bettini L. R.Beretta I. +
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 01 - Articolo su rivista 2024 Cazzaniga M. E. +
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 01 - Articolo su rivista 2024 Bonfanti P.Lombardi A.Invernizzi P.Gerussi A.Citerio G.Biondi A.Valsecchi M. G.Cazzaniga M. E.Foti G.Bettini L. R. +
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M.Antonazzo I. C.Mantovani L. G.Cortesi P. A. +